Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance

• Главные авторы: Yong-Fu Qiu (Автор), Lian-Hua Song (Автор), Gang-Long Jiang (Автор), Zhen Zhang (Автор), Xu-Yan Liu (Автор), Guan Wang (Автор)
• Формат: ‌
• Опубликовано: Georg Thieme Verlag KG, 2022-12-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Anaplastic lymphoma kinase (ALK) is one of the most popular targets for anticancer therapies. In the past decade, the use of anaplastic lymphoma tyrosine kinase inhibitors (ALK-TKIs), including crizotinib and ceritinib, has been a reliable and standard options for patients with lung cancer,...